Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jun 9;82(2):352–361. doi: 10.1111/bcp.12950

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 The British Pharmacological Society

PMC Copyright notice

Mean (± SD) plasma concentrations on day 7 of (A) ticagrelor ( ticagrelor 45 mg (n = 12), ticagrelor 60 mg (n = 12), ticagrelor 90 mg (n = 12)) and (B) AR‐C124910XX ( ticagrelor 45 mg (n = 12), ticagrelor 60 mg (n = 12) and ticagrelor 90 mg (n = 12)) in Chinese patients with stable coronary artery disease treated with low dose aspirin plus ticagrelor 45 mg, 60 mg or 90 mg (single dose on days 1 and 7 and twice daily dosing on days 3–6). Note: data were collected at the time points listed in the Methods section but data points are offset to avoid overlap

Inline graphic — Mean (± SD) plasma concentrations on day 7 of (A) ticagrelor ( ticagrelor 45 mg (n = 12), ticagrelor 60 mg (n = 12), ticagrelor 90 mg (n = 12)) and (B) AR‐C124910XX ( ticagrelor 45 mg (n = 12), ticagrelor 60 mg (n = 12) and ticagrelor 90 mg (n = 12)) in Chinese patients with stable coronary artery disease treated with low dose aspirin plus ticagrelor 45 mg, 60 mg or 90 mg (single dose on days 1 and 7 and twice daily dosing on days 3–6). Note: data were collected at the time points listed in the Methods section but data points are offset to avoid overlap